NovoRapid Administration Blood Glucose Threshold
NovoRapid (insulin aspart) should be administered when blood glucose is ≥200 mg/dL (11.1 mmol/L) in the inpatient setting, based on current guideline consensus for treating hyperglycemia. 1
Blood Glucose Thresholds by Clinical Setting
Inpatient/Hospital Setting
- Initiate rapid-acting insulin (NovoRapid) when blood glucose ≥200 mg/dL as part of a basal-bolus regimen 1
- Target glucose maintenance between 140-180 mg/dL during hospitalization 1
- For DKA management specifically: Continue insulin infusion to keep glucose 150-200 mg/dL until resolution 2
Emergency Department Protocol
Research demonstrates that insulin aspart can be safely initiated in the ED when blood glucose ≥200 mg/dL, with dosing every 2 hours achieving significant glucose reduction (from 304 mg/dL to 217 mg/dL) without increasing hypoglycemia risk 3
Critical Guideline Recommendations
All major diabetes societies (ADA, AACE, Endocrine Society, Diabetes Canada) recommend basal-bolus insulin regimens over sliding scale insulin alone for inpatient hyperglycemia management 1. This means:
- NovoRapid should be given as scheduled prandial (mealtime) insulin, not just for correction
- Combine with basal insulin (not as monotherapy)
- Avoid exclusive sliding scale approaches
Exception for Lower Thresholds
Patients with blood glucose <180 mg/dL on admission who are stable and eating regularly may continue their home oral medications rather than requiring insulin 1
Practical Dosing Algorithm
- Blood glucose ≥200 mg/dL: Initiate basal-bolus regimen with NovoRapid as prandial component
- Blood glucose 180-199 mg/dL: Consider continuation of home regimen if stable; add correction insulin as needed
- Blood glucose <180 mg/dL: Continue home medications if appropriate; monitor closely
Important Caveats
⚠️ Common Pitfall: The drug label information provided 4 appears to be for a topical hemorrhoid preparation, NOT insulin aspart. This is clearly erroneous data. Disregard completely.
⚠️ Hypoglycemia Prevention: Do not administer NovoRapid if blood glucose is trending toward or below 70 mg/dL. The research shows comparable or lower hypoglycemia rates with insulin aspart protocols when properly implemented 3, 5
⚠️ Renal Function: Check potassium and renal function before initiating insulin therapy, particularly in acute settings 2
Special Populations
- Elderly patients (≥65 years): NovoRapid demonstrates improved hypoglycemia rates compared to regular insulin aspart in this population 5
- Patients with HbA1c <7.0%: Exercise caution; these patients may need less aggressive thresholds to avoid hypoglycemia 5
- High insulin resistance (>20 units meal bolus): NovoRapid shows particular benefit with reduced hypoglycemia 5
The key principle: NovoRapid is a prandial insulin that requires scheduled dosing with meals when blood glucose is elevated (≥200 mg/dL), not a reactive "sliding scale only" approach. 1